PAK1基因多态性与乳腺癌内分泌治疗的关系

Correlation between PAK1 gene polymorphism and prognosis of endocrine therapy for breast cancer

目的研究p21激活激酶1(PAK1)基因多态性和乳腺癌内分泌治疗的关系。方法采用聚合酶链反应-限制性片段长度多态性方法,对105例接受乳腺癌内分泌治疗患者的PAK1基因rs2298793 T→C多态位点和rs2844327 C→T多态位点进行基因分型,并综合考虑患者的年龄、月经状态、肿瘤大小、病理、手术情况、分期、雌激素受体、孕激素受体、Her-2、内分泌治疗药物等多种影响预后因素,用Cox模型分析PAK1基因型对内分泌治疗至肿瘤进展时间(TTP)的影响。结果rs2298793 C→T多态位点的CT基因型TTP较TT基因型显著缩短(P<0.05);rs2844327 T→C多态位点的TT基因型TTP生存时间较CC基因型明显下降(P<0.05)。结论PAK1基因的单核苷酸多态性和乳腺癌内分泌治疗至TTP有关,可以作为预测疗效的指标。

Objective To investigate the correlation between p21-actived kinase 1（PAK1） gene polymorpbism and prognosis of endocrine therapy for breast cancer. Methods Polymerase chain reaction-restrlction fragment length polymorphism was employed to analyze the genotype of PAK1 gene rs2298793 T→C polymorphism and rs2844327 C→T polymorphism of 105 patients with breast cancer accepting endocrine therapy. Prognostic factors such as age, state of menses, magnitude of tumor, pathological type, condition of operation, clinical stage, estrogen receptor, progesteron receptor, Her-2 and endocrine therapy drug were comprehensively considered, and Cox model was employed to analyze the relation of PAK1 genotype with the time-to-tumor progression （TTP）. Results As to rs2298793C →T polymorphism, the TTP of CT genotype was shorter than TT genotype （P 〈 0.05）. As to rs2844327 T→C polymorphism, the TTP of TT genotype was shorter than CC genotype （ P 〈 0.05）. Conclusion The single nucleotide polymorphism of PAK1 gene is relevant with the TTP of patients accepting endocrine therapy for breast cancer, so it can be used for curative effect prediction.